Abstract
Previous in-vitro data pointed out lithium, an activator of the β-catenin signalling pathway, as a modulator of HIV-1 transcription. We assessed the effect of in-vivo administration of lithium on viral latency modulation in nine antiretroviral therapy (ART)-suppressed HIV-1-infected individuals. We found that lithium carbonate treatment was able to transiently repress HIV-1 residual expression in CD4 T cells in vivo, which led to a concomitant short-term decrease in the proviral reservoir size.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-HIV Agents / pharmacology*
-
DNA, Viral
-
HIV Infections / drug therapy*
-
HIV Infections / genetics
-
HIV Infections / immunology
-
HIV-1* / genetics
-
Humans
-
Linolenic Acids / pharmacology*
-
Lithium Compounds / pharmacology*
-
Proviruses* / genetics
-
Signal Transduction
-
Viral Load / drug effects*
-
Virus Latency / drug effects
-
Virus Latency / immunology
-
Virus Replication
-
beta Catenin / genetics
-
beta Catenin / immunology
Substances
-
Anti-HIV Agents
-
DNA, Viral
-
Linolenic Acids
-
Lithium Compounds
-
beta Catenin